BioSpace News Archive

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 ® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

Ashvattha Therapeutics, a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers, to develop a new class of precision medicines, announced that the Company will provide a corporate overview at two upcoming investor conferences.

Alercell, Inc. announced it has entered into an exclusive distribution agreement with American Lion Holdings in which ALH will commercialize Alercell line of surgical operating tables and equipment for hospitals and surgical centers in several states on the East Coast including New York, New Jersey, Connecticut, Kentucky and Florida.

Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the first production batch has been manufactured and released for Elucirem™ (gadopiclenol) injection following FDA approval on September 21, 2022, after priority review.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that enrollment in the final cohort of the Phase 1b stage of its Cancer Appetite Recovery Study (CAReS) is now complete.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the European Medicines Agency (“EMA”) has agreed to the Company’s proposed Pediatric Investigation Plan (“PIP”) for naxitamab.

Qvin™, the biotechnology company that developed the first and only healthcare service that scientifically collects menstrual blood to test for HR-HPV and other critical healthcare information, announced FDA approval in Thailand for its Q-Pad technology.

AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

GT Biopharma, Inc., a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer cell engager, TriKE® platform, issued an open letter from the CEO to shareholders, detailing the Company’s recent activities.

Psycheceutical Bioscience, Inc. (OTCPK: BWVI) (“Psycheceutical” or the “Company”) is pleased to announce it has completed its pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (FDA) and received positive feedback regarding the Company’s development plans for a novel NeuroDirect™ topical formulation of ketamine, intended for treating post-traumatic stress disorder (PTSD).